A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Patients Who Have Failed to Respond to Steroid Treatment for Acute GVHD
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 09 Apr 2018
At a glance
- Drugs Remestemcel-L (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Mesoblast
- 03 Apr 2018 Planned End Date changed from 1 Mar 2018 to 1 Apr 2018.
- 21 Feb 2018 According to a Mesoblast media release, full results will be provided in CY Q2 2018.
- 21 Feb 2018 According to a Mesoblast media release, results were presented t the tandem annual scientific meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society of Blood and Marrow Transplantation (ASBMT) 2018.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History